Home > Organization > Supportive Care Project > Research Summary
- Development and development support for novel drugs for cancer patients with cachexia and patients with anticancer drug that possess cardiotoxicity
Development of novel drugs for the improvement of cardiotoxicity. Desacylghrelin and its specific novel receptors are attractive candidates.
- Cancer patients with cachexia and patients with anticancer drugs that possess cardiotoxicity
- Creation and clinical development of novel opioid preparations (μ/δ opioid dimerized receptor-specific agonists that cause less side effects)
Opioids are used as strong analgesics in cancer patients; however, they show several types of side effects and tolerance as well. In the project, functions and properties of opioid receptors (μ, δ and κ) have been extensively studied. As a result, we have been able to develop novel μ/δ heterodimer-specific agonists with strong analgesic effects but less tolerance and fewer side effects.
- Cancer patients with opioid tolerance and cancer patients having side effects due to opioids
- Establishment and implementation in detection system of biomarkers of delirium that predicts its onset, with analysis of bloods from patients undergoing long-term cancer surgery
We identified novel biomarkers that predicts onset of delirium with bloods from cancer patients underwent long-term surgery. They were identified with the methods of metabolome analysis and measurement of particular cytokines and hormones from the bloods. We will establish and implement system for detection of biomarkers that predict delirium onset in the clinic.
- Cancer patients undergoing long-term cancer surgery and the patients treated in the ICU